Results 141 to 150 of about 5,926 (192)

Targeting fatty acid synthase to overcome PARP inhibitor resistance and to create an artificial synthetic lethality for triple-negative breast cancer. [PDF]

Genes Dis
Josephraj S, Wang CJ, Cui Q, Dong Z, Liu JY, Zhang JT.   +5 more
europepmc   +1 more source

Incidentally Detected Ductal Adenocarcinoma Presenting With Isolated Pulmonary Metastasis and a BRCA2 Mutation. [PDF]

IJU Case Rep
Karasawa H, Kosaka T, Komatsuda A, Baba Y, Nakamura K, Nishihara H, Oya M.   +6 more
europepmc   +1 more source

The Impact of Novel Therapies on Quality-of-Life in Triple-Negative Breast Cancer: A Systematic Review of Clinical Trials. [PDF]

Cancers (Basel)
Kamau B, Shulimovich M, Samridhi S.
europepmc   +1 more source

PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1/2 and MTAP status in breast cancer cells. [PDF]

Sci Rep
Suresh S, McPherson L, Ford JM.
europepmc   +1 more source

Talazoparib nanoparticles for overcoming multidrug resistance in triple‐negative breast cancer

Journal of Cellular Physiology, 2020
AbstractHerein, we investigated efflux pumps‐mediated talazoparib‐resistance in the treatment of triple‐negative breast cancer (TNBC). Furthermore, we produced a novel talazoparib‐solid lipid nanoparticles (SLNs) and then explored in vitro therapeutic efficacy of talazoparib‐SLNs to overcome talazoparib‐resistance in TNBC cells.
Gamze Guney Eskiler, Gülşah Çeçener, Ünal EGELİ   +2 more
exaly   +7 more sources